OMER
Omeros' Q4 2025: A Turning Point for the Biotech Company
Omeros, a biopharmaceutical company, marked a significant milestone in its fourth quarter of 2025 with two major successes that have set the stage for future growth and expansion. On November 25, Omeros closed an asset purchase and license transaction with Novo Nordisk for its phase III-ready asset zaltenibart, while on